FINWIRES · TerminalLIVE
FINWIRES

Natera's Signatera CDx Approved by FDA as Companion Diagnostic in Muscle-Invasive Bladder Cancer

By

Natera (NTRA) said Friday the US Food and Drug Administration approved Signatera CDx as a companion diagnostic for use with adjuvant atezolizumab to treat muscle-invasive bladder cancer.

The approval follows phase 3 trial results that showed Signatera molecular residual disease-positive patients treated with immunotherapy achieved improvements in disease-free survival and overall survival, while MRD-negative patients achieved 97% two-year OS with no adjuvant therapy, the company said.

Price: $189.00, Change: $-7.91, Percent Change: -4.02%

Related Articles

Australia

Investor Bill Ackman Says Pershing Hedge Fund Sold Alphabet, Bought Microsoft

Bill Ackman said Friday on the social media platform X that his Pershing Square hedge fund has sold Alphabet (GOOG, GOOGL) shares and established a new position in Microsoft (MSFT).Pershing began buying Microsoft in February after a notable share price decline following its fiscal Q2 results, acquiring a position at a valuation of 21 times forward earnings, in line with the market multiple and well below Microsoft's trading average over the last few years, Ackman said.Ackman said investors underestimate the resilience of the Microsoft 365 franchise given its embedded role across enterprises and highly attractive price-to-value proposition, according to the X post.Concerns regarding the growth trajectory of Microsoft's Azure cloud business are similarly misplaced, especially after the franchise's exceptional recent performance, he added."We believe that $MSFT offers analogous and compelling long-term value at today's valuation," Ackman said on X.Price: $392.13, Change: $-5.04, Percent Change: -1.27%

$GOOG$GOOGL$MSFT
Australia

Thermo Fisher Likely to Benefit From End-Market Recovery, but Structural Risks Remain, RBC Says

Thermo Fisher Scientific (TMO) could benefit from improving end-market conditions and recovering biotech funding, though "structural risks" may limit the company's ability to achieve its long-term organic growth aspiration, RBC Capital Markets said in a report emailed Friday."Investor skepticism" surrounding Thermo Fisher's 2026 guidance and broader post-pandemic recovery trends "is well-founded" after several years of uneven "normalization" across the life sciences tools industry, RBC noted. Still, the firm said recovery prospects appear "more plausible" as uncertainty in large pharmaceutical and academic markets begin to ease.The firm said normalized organic growth closer to 5% may be as likely as management's 7%-plus target and the Wall Street's roughly 6% forecast. It also pointed to "lingering" artificial intelligence uncertainty surrounding the long-term outlook for the company's contract research organization business, which represents about 20% of sales, according to the report.RBC resumed coverage of Thermo Fisher with a sector perform rating and a $490 price target.Price: $442.17, Change: $-6.04, Percent Change: -1.35%

$TMO
Australia

Market Chatter: BP to Cut Pipeline Gas Trading Team, Focus More on LNG

BP (BP) plans to cut its pipeline gas trading team and focus on expanding its liquified natural gas trading, Reuters reported Friday, citing two sources familiar with the matter.The oil major will lay off about 20 people on the pipeline gas team and fold the remaining workers into its LNG book, the report said, citing the sources.BP didn't immediately reply to a request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $44.10, Change: $+0.47, Percent Change: +1.09%

$BP